A 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate CEP of the European Pharmacopoeia monograph is often referred to as a 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate Certificate of Suitability (COS). The purpose of a 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate to their clients by showing that a 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate CEP has been issued for it. The manufacturer submits a 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate CEP (COS) as part of the market authorization procedure, and it takes on the role of a 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate CEP holder for the record. Additionally, the data presented in the 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate DMF.
A 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of 1,4-Bis(2-ethylhexyl) sodium sulfosuccinate suppliers with CEP (COS) on PharmaCompass.